(Q48350500)

10 February 2018

title

From triazines and triazenes to temozolomide (English)

1 reference

10 February 2018

0 references

M F Stevens

1

1 reference

10 February 2018

E S Newlands

series ordinal

2

1 reference

10 February 2018

publication date

1 January 1993

1 reference

10 February 2018

European Journal of Cancer

published in

1 reference

10 February 2018

volume

29A

1 reference

10 February 2018

issue

7

1 reference

10 February 2018

page(s)

1045-1047

1 reference

10 February 2018

Antitumor imidazotetrazines. 1. Synthesis and chemistry of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3 H)-one , a novel broad-spectrum antitumor agent

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980221-7

7 January 2021

Studies on the mechanism of action of the tumour inhibitory triazenes

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980221-7

7 January 2021

Alteration of DNA by 5-(3-methyl-1-triazeno)imidazole-4-carboxamide (NSC-407347)

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980221-7

7 January 2021

Antitumor imidazotetrazines. 20. Preparation of the 8-acid derivative of mitozolomide and its utility in the preparation of active antitumor agents

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980221-7

7 January 2021

General guidelines for the preclinical toxicology of new cytotoxic anticancer agents in Europe. Joint Steering Committee of the European Organization for Research and Treatment of Cancer (EORTC) and the Cancer Research Campaign (CRC)

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980221-7

7 January 2021

Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980221-7

7 January 2021

Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980221-7

7 January 2021

Antitumor imidazotetrazines. 25. Crystal structure of 8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (temozolomide) and structural comparisons with the related drugs mitozolomide and DTIC.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980221-7

7 January 2021

EGF receptor amplification and expression in human brain tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980221-7

7 January 2021

Antitumor 1-(X-aryl)-3,3-dialkyltriazenes. 2. On the role of correlation analysis in decision making in drug modification. Toxicity quantitative structure-activity relationships of 1-(X-phenyl)-3,3-dialkyltriazenes in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980221-7

7 January 2021

10.1016/S0959-8049(05)80221-7

Identifiers

DOI

1 reference

10 February 2018

1 reference

10 February 2018